Eupraxia Pharmaceuticals (EPRX) Interest & Investment Income (2023 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Interest & Investment Income came in at $1.1 million in Q1 2026, up 247.09% year-on-year from $309452.0 in Q1 2025, and up 61.05% on a QoQ basis from $666921.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Interest & Investment Income (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 4 years of Interest & Investment Income data on file, last reported at $1.1 million in Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 247.09% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $2.2 million, a 76.57% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 21.77% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $1.1 million, up from $666921.0 in the prior quarter.
- Over the last five years, Interest & Investment Income for EPRX reached as high as $1.1 million in Q1 2026 and fell as low as $152271.0 in Q2 2023.
- Historically, Interest & Investment Income has averaged $346884.6 across 4 years, with a median of $255958.0 in 2025.
- Across the five-year window, Interest & Investment Income sank 40.8% in 2025 and jumped 247.09% in 2026, its largest moves.
- Year by year, Interest & Investment Income stood at $353790.0 in 2023, then tumbled by 38.38% to $218006.0 in 2024, then jumped by 205.92% to $666921.0 in 2025, then jumped by 61.05% to $1.1 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $1.1 million in Q1 2026, $666921.0 in Q4 2025, and $180185.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Eupraxia Pharmaceuticals | 350.77 Mn | 350.77 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 666,921.00 |
| Sep 30, 2025 | 180,185.00 |
| Jun 30, 2025 | 255,958.00 |
| Mar 31, 2025 | 309,452.00 |
| Dec 31, 2024 | 218,006.00 |
| Sep 30, 2024 | 304,342.00 |
| Jun 30, 2024 | 401,226.00 |
| Mar 31, 2024 | 236,369.00 |
| Dec 31, 2023 | 353,790.00 |
| Sep 30, 2023 | 193,875.00 |
| Jun 30, 2023 | 152,271.00 |
| Mar 31, 2023 | 163,033.00 |